Sign in

    Sol Zelman

    Research Analyst at Gericare

    Sol Zelman is Director of Sales and Business Development at Gericare Pharmaceuticals, specializing in pharmaceutical sales and strategic business growth within the healthcare and nutraceutical sectors. He oversees the Teelah Nutraceutical Division and has driven expansion through a portfolio covering companies such as Teelah Nutraceuticals and Gericare Pharmaceuticals, with a sales leadership record since 2018. Previously, Zelman was Sales Manager at Stella Pharmaceutical Canada Inc. from 2013 to 2018 and managed customer service and HR at Prime Source Services LLC from 2010 to 2013, following studies at BMTC Institute for Higher Education. His credentials include extensive leadership in sales and marketing, though formal securities licenses or FINRA registration are not listed.

    Sol Zelman's questions to Nano Dimension (NNDM) leadership

    Sol Zelman's questions to Nano Dimension (NNDM) leadership • Q3 2024

    Question

    Sol Zelman inquired about the risk of activist shareholder Murchinson derailing the pending acquisitions of Desktop Metal and Markforged if they succeed in installing two directors on the board, and also asked for more details on the CFIUS regulatory process.

    Answer

    Executive Yoav Stern explained that the CFIUS process is a standard regulatory review that is nearly complete for Desktop Metal and expected to be efficient for Markforged. Regarding the activist threat, Stern downplayed the risk, stating that two directors would be a minority on an eight-person board and could not legally derail deals that are already signed and committed. He expressed confidence that the transactions would proceed as planned, despite his general cautiousness about unexpected events.

    Ask Fintool Equity Research AI